

# The role of Global Health EDCTP3 JU towards fighting infectious diseases

Lisbon

12 April 2024



Co-funded by  
the European Union

# The evolution of EDCTP programmes

## EDCTP1: 2004-2015

## EDCTP2: 2014-2024 (2026)

## Global Health EDCTP3: 2022-2031

- Legal structure: **European Economic Interest Grouping (EEIG)**
- Supported under European Commission's FP6/FP7
- Total budget: €400 M (European Union: €200M; Participating States: €200M) and Third parties: €200M
- Disease scope: HIV, tuberculosis and malaria

- Legal structure: **EDCTP Association**
- Supported under European Union's Horizon 2020
- Total budget: €1.36Bn (European Union: €683M; Participating States: €683M) and third parties: €500M
- Disease scope: HIV, TB, malaria, NIDs, diarrhoeal diseases, lower respiratory tract infections, *infectious diseases of epidemic potential*

- Legal structure: **Joint Undertaking between the European Commission and the EDCTP Association**
- Sources of funding: (JU members and contributing partners)
- Total budget: More than €1.7Bn (EU Horizon Europe: €800M; Participating States: €550M; Contributing partners: €400M)
- Disease scope: HIV, TB, malaria, NIDs, diarrhoeal diseases, lower respiratory tract infections, and infectious diseases of epidemic potential

antimicrobial resistance (AMR), climate crisis-provoked changes ID incidence, **co-infections and co-morbidities**, incl. co-morbid **non-communicable** conditions



Co-funded by  
the European Union

# Global Health EDCTP3 strategic approach

## Vision:

To reduce the individual, social, and economic burden of poverty-related infectious diseases, including the neglected, emerging, and re-emerging infectious diseases, in sub-Saharan Africa (SSA).

## Mission:

To support global collaborative research, capacity strengthening, and international initiatives to **accelerate the development, evaluation, and implementation** of interventions to prevent, identify, and treat infectious diseases and emerging/re-emerging infections in SSA to reduce overall mortality and morbidity.

## Overall objectives:

- Reduction of the socioeconomic burden of infectious diseases in SSA by **accelerating the development and uptake of new or improved health technologies**
- Increase of health security in SSA and globally by **strengthening the research- and innovation-based capacities** for preparedness and response to control infectious diseases.



Advance biomedical interventions towards improved overall health.



Research capacity development.



Enhance coordination and alignment of countries around a common SRIA.



Strengthen capacity for outbreaks/ epidemic/ pandemic preparedness.



Networking, building partnerships and strategic alliances.

# Current EDCTP Association Members

## European Countries


- |            |                 |                    |
|------------|-----------------|--------------------|
| 1. Austria | 6. Germany      | 11. Norway         |
| 2. Belgium | 7. Ireland      | 12. Portugal       |
| 3. Denmark | 8. Italy        | 13. Spain          |
| 4. Finland | 9. Luxembourg   | 14. Sweden         |
| 5. France  | 10. Netherlands | 15. United Kingdom |

## African countries


- |                                     |                    |                  |
|-------------------------------------|--------------------|------------------|
| 1. Benin                            | 10. Ghana          | 20. Rwanda       |
| 2. Burkina Faso                     | 11. Guinea-Bissau  | 21. Senegal      |
| 3. Cameroon                         | 12. Guinea-Conakry | 22. Sierra Leone |
| 4. Cote d'Ivoire                    | 13. Kenya          | 23. Somalia      |
| 5. Democratic Republic of the Congo | 14. Liberia        | 24. South Africa |
| 6. Congo                            | 15. Mali           | 25. Tanzania     |
| 7. Ethiopia                         | 16. Malawi         | 26. Uganda       |
| 8. Gabon                            | 17. Mozambique     | 27. Zambia       |
| 9. The Gambia                       | 18. Niger          | 28. Zimbabwe     |
|                                     | 19. Nigeria        |                  |

## Aspirant members


1. Angola
2. Switzerland



# GH EDCTP3 JU integrated approach & scope



# Clinical studies to be supported by GH EDCTP3




# Criteria for prioritisation of funding:

- Product development landscape: comprehensive analysis of the current clinical development status of medical interventions and innovations relevant to Global Health EDCTP3
- Priority infections: consideration of priority infections based on disease burden, patterns, co-morbidities, co-infections and potential for public health crisis
- Global and regional priorities: identification of R&D priorities and capacity-building needs, addressing policy and knowledge gaps to support evidence-based policy and practice
- Addressing translational bottlenecks: effectiveness studies, pharmacovigilance and product-focused implementation research to overcome translational bottlenecks hindering clinical development and adoption of novel interventions
- Strategic partnerships: collaboration with like-minded partners to enhance regional and global alignment, delivering coordinated responses to policy and public health challenges, leveraging EU initiatives and previous EDCTP investments
- Balanced portfolio of grants: well-balanced allocation of resources across disease areas, interventions and study designs to maximise impact and address diverse health needs effectively.

# Building on EDCTP1 & EDCTP2 previous investments

2003-2023





# Global Health EDCTP3: facts and figures

2022-2024



**€372 M**

is the budget for the **20 calls for proposals** launched to date (2022, 2023 & 2024)



**€103 M**

is the total funding for **28 ongoing projects** (2022 calls for proposals)



**€95.4 M**

for **19 grants supporting R&I projects including clinical trials & other clinical research activities** conducted by European-African consortia.



**€7.6 M**

for **9 grants** supporting coordination and strengthening institutional capacities and the enabling **environment for conducting clinical trials and clinical research**



With a total budget of **€130 million** from the 2023 calls for proposals, **close to 40 new projects** will start in the coming months

## 2024 Work Programme: 7 thematic topics (EUR140 plus)

Topic Code	Call Topic Title	Budget (EUR)
HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage	Developing novel, innovative <b>HIV therapeutics</b> for reducing the disease burden of HIV in sub-Saharan Africa	22M
HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage	Research on existing <b>Malaria vaccines</b> and development of new promising candidates	30M
HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage	Accelerating development and integration of <b>therapeutics</b> against <b>Neglected Tropical Diseases (NTDs)</b> in SSA	22M
HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage	Tackling <b>Antimicrobial Resistance (AMR)</b> through R&D in novel and existing antimicrobials	24M
HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage	New tools, technologies and approaches for <b>vector control</b> in sub-Saharan Africa	18.4M
HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage	Innovative <b>digital health</b> solutions for sub-Saharan Africa	20M
HORIZON-JU-GH-EDCTP3-2024-02-01-two-stage	Global Health EDCTP3 JU training <b>fellowship with reintegration phase</b>	3.5M



+ Mobilisation of research funds in case of public health emergencies - 1M

**What are some of the success stories that  
EDCTP has delivered so far?**



Co-funded by  
the European Union



Since  
2003

€4+ billion  
funding

43  
countries

- Antimicrobial resistance
- Climate crisis impact
- Co-infections & co-morbidities

- HIV
- Tuberculosis
- Malaria
- Neglected infectious diseases
- Diarrhoeal diseases
- Lower respiratory tract infections
- Infectious diseases of epidemic potential




Co-funded by  
the European Union

# Building a clinical trial ecosystem and infrastructure

In partnership with local & global partners



and more than 70 countries



## Africa

- 1.3 billion population
- 66% HIV, 24% TB global burden
- 0,45% of R&D investment
- 0,1% vaccine production



Advance biomedical interventions



Research capacity development



Epidemic & pandemic preparedness



Networking, partnerships &  
strategic alliances



To reduce the individual, social and economic burden of infectious diseases in sub-Saharan Africa and to strengthen research capacities



**300+**  
Clinical trials  
funded

**2000+**  
African researchers  
supported

# A new malaria vaccine for children

**R21/Matrix M**

Recommended by  **World Health Organization**



Home / News / WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization



**WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization**

العربية 中文 Français Русский Español

THE LANCET

**Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial**

*Mehreen S Datto\*, Magloire H Natama\*, Athanase Somé, Ousmane Traoré, Toussaint Rouamba, Duncan Bellamy, Prisca Yameogo, Daniel Valia, Moubarak Tegneri, Florence Ouedraogo, Rachidatou Soma, Seydou Sawadogo, Faizatou Sorgho, Karim Derra, Eli Rouamba, Benedict Orindi, Fernando Ramos Lopez, Amy Flaxman, Federica Cappuccini, Reshma Kailath, Sean Elias, Ekta Mukhopadhyay, Andres Noe, Matthew Cairns, Alison Lawrie, Rachel Roberts, Innocent Valéa, Hermann Sorgho, Nicola Williams, Gregory Glenn, Louis Fries, Jenny Reimer, Katie J Ewer, Umesh Shaligram, Adrian V S Hill, Haldou Tiatra*



# A simpler and safer treatment for cryptococcal meningitis

**Liposomal amphotericin B**

Rapid advice from  **World Health Organization**



*The* **NEW ENGLAND**  
**JOURNAL** *of* **MEDICINE**

ESTABLISHED IN 1812

MARCH 24, 2022

VOL. 386 NO. 12

## Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis

J.N. Jarvis, D.S. Lawrence, D.B. Meya, E. Kagimu, J. Kasibante, E. Mpoza, M.K. Rutakingirwa, K. Ssebambulidde, L. Tugume, J. Rhein, D.R. Boulware, H.C. Mwandumba, M. Moyo, H. Mzinganjira, C. Kanyama, M.C. Hosseinipour, C. Chawinga, G. Meintjes, C. Schutz, K. Comins, A. Singh, C. Muzoora, S. Jjunju, E. Nuwagira, M. Mosepele, T. Leeme, K. Siamisang, C.E. Ndhlovu, A. Hlupeni, C. Mutata, E. van Widenfelt, T. Chen, D. Wang, W. Hope, T. Boyer-Chammard, A. Loyse, S.F. Molloy, N. Youssouf, O. Lortholary, D.G. Lalloo, S. Jaffar, and T.S. Harrison, for the Ambition Study Group\*

# The first oral treatment for sleeping sickness

**Fexinidazole Winthrop**

In partnership with **DNDi**



Positive opinion by **EUROPEAN MEDICINES AGENCY**  
SCIENCE MEDICINES HEALTH



© EDCTP

# A new treatment for schistosomiasis in children

**Arpraziquantel**

Positive opinion by



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH



Global Health  
EDCTP3

# Preventing and treating Lassa fever



© CEPI

In partnership with the national  
centres for disease control and **CEPI**

# Vaccine manufacturing in Africa



In partnership with national governments and



‘The most cited joint programme strengthening health research and health systems in Africa and the flagship EU-Africa partnership in health R&D cooperation, with large successful long-lasting research networks’.

Advisory Group on R&I for Africa-Europe cooperation



Co-funded by  
the European Union

'A successful initiative which has developed sustainable capacities and supported local leadership in many African countries'.

WHO



Co-funded by  
the European Union



Clear focus



Collaborative approach



Retention of talent



Equality



© EDCTP

From a funding instrument for collaborative research to  
an important global health movement



# Thank you



Co-funded by  
the European Union